Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ImageneBio ( (IMA) ) just unveiled an announcement.
ImageneBio announced on October 23, 2025, that it will not automatically renew its transition services agreement with Miragene Inc. Instead, the company has opted to extend the term for six months for a subset of services, including chemistry, manufacturing and controls, and translational sciences research. The extension services will incur a total fee of $200,000. This decision reflects ImageneBio’s strategic approach to managing its operational needs and collaborations, potentially impacting its service delivery and stakeholder relationships.
The most recent analyst rating on (IMA) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on ImageneBio stock, see the IMA Stock Forecast page.
Spark’s Take on IMA Stock
According to Spark, TipRanks’ AI Analyst, IMA is a Neutral.
Ikena Oncology’s overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.
To see Spark’s full report on IMA stock, click here.
More about ImageneBio
Average Trading Volume: 62,926
Technical Sentiment Signal: Sell
Current Market Cap: $97.28M
For a thorough assessment of IMA stock, go to TipRanks’ Stock Analysis page.